CESCA THERAPEUTICS INC. (NASDAQ:KOOL) Files An 8-K Financial Statements and ExhibitsItem 9.01 would be filed within 71 days after the date on which the Current Report on Form 8-K was required to be filed. This amended Current Report on Form 8-K/A contains the required financial statements and pro forma financial information.
| Item 9.01. |
Financial Statements and Exhibits. |
| (a) |
Financial Statements of Business Acquired. |
SynGen Inc.’s audited consolidated financial statements as of and for the years ended December 31, 2016 and 2015 are attached hereto as Exhibit 99.2. SynGen Inc.’s unaudited condensed consolidated financial statements as of June 30, 2017 and December 31, 2016 and for the six months ended June 30, 2017 and 2016 are attached hereto as Exhibit 99.3.
| (b) |
Pro Forma Financial Information. |
The unaudited pro forma condensed combined financial information for the Company, after giving effect to the SynGen Transaction and adjustments described in such pro forma financial information, for the year ended June 30, 2017, are attached hereto as Exhibit 99.4.
The following exhibits are attached to this Current Report on Form 8-K:
|
Exhibit No. |
Description |
|
2.1 |
Asset Acquisition Agreement, dated July 7, 2017, between SynGen Inc. and ThermoGenesis Corp (incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K (File No. 333-82900) filed on July 11, 2017).* |
|
10.1 |
Voting Agreement, dated July 7, 2017, among ThermoGenesis Corp., Cesca Therapeutics Inc., Bay City Capital Fund V, L.P., and Bay City Capital Fund V Co-Investment Fund, L.P. (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K (File No. 333-82900) filed on July 11, 2017). |
|
10.2 |
Investors’ Rights Agreement, dated July 7, 2017, among ThermoGenesis Corp., Bay City Capital Fund V, L.P., and Bay City Capital Fund V Co-Investment Fund, L.P. (incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K (File No. 333-82900) filed on July 11, 2017). |
|
10.3 |
Right of First Refusal and Co-Sale Agreement, dated July 7, 2017, among ThermoGenesis Corp., Cesca Therapeutics Inc., Bay City Capital Fund V, L.P., and Bay City Capital Fund V Co-Investment Fund, L.P. (incorporated by reference to Exhibit 10.3 to the Company’s Form 8-K (File No. 333-82900) filed on July 11, 2017). |
*Schedules have been omitted to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the Securities and Exchange Commission upon request.
CESCA THERAPEUTICS INC. ExhibitEX-23.1 2 ex_95773.htm EXHIBIT 23.1 ex_95773.htm Exhibit 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements of Cesca Therapeutics Inc. on Form S-3 (Nos. 333-215638 and 333-212314) and Form S-8 (Nos. 333-218082,…To view the full exhibit click here
About CESCA THERAPEUTICS INC. (NASDAQ:KOOL)
Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.